Blog | HemaCare

Dendritic Cell Immunotherapy Gets a Boost

Jul 25, 2016 1:00:30 PM / by Steffen Porwollik posted in glioma, brain cancer, Cancer Immunology, cancer immunotherapy, cytotoxic T cells, Dendritic cells, immunogenic cell death, Innovation, T cells

0 Comments

A new strategy significantly increases the efficacy of dendritic cell immunotherapy against high grade glioma, a severe type of brain cancer. The key: pre-exposing the therapy to glioma cells undergoing immunogenic cell death.

High grade glioma (HGG) is a malignant brain cancer that is characterized by tumorous growth of glial cells, non-neural cells surrounding the neurons of the central and peripheral nervous system. HGG is accompanied by a heartbreakingly poor prognosis and the current lack of a cure. Hundreds of children are diagnosed every year with HGG in Europe and North America.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts